ATANIS Biotech AG completes an oversubscribed Capital Increase and accelerates marketing efforts

In Bern, Switzerland, on October 22th, 2024

ATANIS Biotech AG, a Swiss company specializing in functional allergy diagnosis, today announced they had successfully completed an oversubscribed capital raise. The round was led by Spectrum Moonshot Fund, an investment vehicle backed by a prominent Swiss family with a strong focus on high-growth technology startups. Additional funding was provided by seasoned investors in the allergy sector, along with contributions from existing backers. ATANIS Biotech also generates revenue by serving over 20 institutional clients from pharma, biotech, and agri-food industry with different needs ranging from pre-clinical compound screening to efficacy assessment of selected drug candidates.

"I am delighted to have completed this oversubscribed capital increase in record time" said Pr. Dr. Jean-Pierre Kinet, CEO of ATANIS Biotech. "*This will enable us to accelerate our marketing efforts of FAST-PASE® in the United States and Europe, and help us to more rapidly address the urgent need for a safe, functional* ex vivo *allergy assay for patients"*

As part of this capital raise, Mr. Jascha Forster has joined the board of the company, where he will contribute his expertise in financing and management of rapid growth enterprises. *"I look forward to working with ATANIS' leadership team and better serve allergy patients"*, declared Mr. Forster.

ATANIS Biotech is pursuing regulatory approval of its proprietary mast cell activation test for use in a clinical setting in the US, EU, and Switzerland. Discussions with the FDA are underway to bring FAST-PASE® to the US market as fast as possible.

About ATANIS Biotech AG:

The company is focused on revolutionizing allergy diagnosis. Current diagnostic procedures for allergy rely on risky, uncomfortable, cumbersome, and outdated functional *in vivo* allergen exposures. ATANIS has developed a novel, functional ex vivo mast cell activation test, named FAST-PASE®. The assay uses shelf-stable patient serum, which enables scalability. In recent diagnostic accuracy studies FAST-PASE® has outperformed other established clinical methods and procedures to identify allergies.

Contact:

Erwan Eriau, COO

info@atanis-biotech.com

https://www.atanis-biotech.com

https://www.linkedin.com/company/atanis-biotech/